Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Cameron Santoro is an associate editor for The Center for Biosimilars

Articles

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults with type 2 diabetes.

Dulaglutide Biosimilar LY05008 Shows Efficacy and Safety in Treating Type 2 Diabetes

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability.

Year-Long Phase 3 Study Confirms Tocilizumab Biosimilar Comparability With Actemra

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

Postmarketing Surveillance Data Reinforce Trastuzumab Biosimilar Safety in HER2+ Gastric Cancer

Videos

Here are the top 5 biosimilar articles for the week of July 28, 2025.

The Top 5 Biosimilar Articles for the Week of July 28

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

The Center for Biosimilars - Biosimilars, Health Economics & Insights

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

View

AMCP: Academy of Managed Care Pharmacy

Conference

Business & Practice

Magellan Rx Pharmacists Discuss Why All Biosimilars Are Not Added to Formularies 

Magellan Rx Pharmacists: Why Payers Should Be More Invested in Promoting Biosimilars

Magellan Rx Pharmacists: Current Biosimilar Market Trends in Oncology

Magellan Rx Pharmacists: What Disease States Have Better Biosimilar Uptake?

Magellan Rx Pharmacist: How to Encourage Payers to Prefer Biosimilars

Magellan Rx Pharmacists: Which Formulary Placement Is Most Beneficial for Biosimilar Uptake?

Magellan Rx Pharmacist: What Is the Cure for Rebate Addiction?

Magellan Rx Pharmacists: What the US can Learn from Europe's Biosimilar Industry

Magellan Rx Pharmacists: What Can Payers Do to Boost Biosimilar Uptake?

Magellan Rx Pharmacist: Cost Savings Potential if Oncology Biosimilar Utilization Increased

Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management talk about how market trends, payer formulary decisions, and international successes are shaping today's biosimilars industry.

Clinical

Magellan Rx Pharmacists Explore the Payer Perspective on Oncology Biosimilars

Magellan Rx Pharmacists Explore the Payer Perspective on Oncology Biosimilars

Newsletter